This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 May;9(5):404.

doi: 10.1016/j.jchf.2021.02.010.

Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy

Claudio Rapezzi, Marla B Sultan, Mathew S Maurer

PMID: 33926735
DOI: 10.1016/j.jchf.2021.02.010

Free article

Comment

Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy

Claudio Rapezzi et al. JACC Heart Fail. 2021 May.

Free article

. 2021 May;9(5):404.

doi: 10.1016/j.jchf.2021.02.010.

Authors

Claudio Rapezzi, Marla B Sultan, Mathew S Maurer

PMID: 33926735
DOI: 10.1016/j.jchf.2021.02.010

No abstract available

PubMed Disclaimer

Comment on

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Rapezzi C, et al. JACC Heart Fail. 2021 Feb;9(2):115-123. doi: 10.1016/j.jchf.2020.09.011. Epub 2020 Dec 9. JACC Heart Fail. 2021. PMID: 33309574
Bio-Profiling of Transthyretin Amyloid Cardiomyopathy.
Mehmood M. Mehmood M. JACC Heart Fail. 2021 May;9(5):403-404. doi: 10.1016/j.jchf.2020.12.016. JACC Heart Fail. 2021. PMID: 33926733 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program